Involvement of upstream open reading frames in regulation of rat V1b vasopressin receptor expression

Atsushi Nomura1, Yasumasa Iwasaki2, Masayuki Saito3, Yoshiaki Aoki1, Etsuko Yamamori1, Nobuaki Ozaki1, Kazushige Tachikawa1, Noriko Mutsuga1, Minako Morishita1, Masanori Yoshida1, Masato Asai1, Yutaka Oiso1, and Hidehiko Saito1

1 First Department of Internal Medicine and 2 Department of Clinical Laboratory Medicine, Nagoya University School of Medicine and Hospital, Nagoya 466-8560; and 3 Molecular Medicine Research Laboratories, Yamanouchi Institute for Drug Discovery Research, Tsukuba 305-0841, Japan


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The V1b vasopressin receptor, expressed mainly in the corticotroph of the anterior pituitary, mediates the stimulatory effect of vasopressin on ACTH release. To clarify the regulation of receptor expression, we cloned, sequenced (up to ~5 kb from the translation start site), and characterized the 5'-flanking region of the rat V1b receptor gene. We identified the transcription start site by amplification of cDNA ends and found a new intron within the 5'-untranslated region (5'-UTR) by comparing the sequence with that of cDNA. We then confirmed that the obtained promoter indeed has transcriptional activity by use of the luciferase reporter in AtT-20 mouse corticotroph cells. Interestingly, there were five short upstream open reading frames (uORFs) located within the 5'-UTR that were found to suppress V1b expression. Subsequent mutational analyses showed that the two downstream uORFs have an inhibitory effect on expression in both homologous and heterologous contexts. Furthermore, the inhibition did not accompany a parallel decrease in mRNA, suggesting that the suppressive effect occurs at a level downstream of transcription. Taken together, our data strongly suggest that the expression of the V1b receptor is regulated at the posttranscriptional as well as transcriptional level through uORFs within the 5'-UTR region of the mRNA. Whether the uORF-mediated regulation of V1b expression is functionally linked to any intracellular and/or extracellular factor(s) awaits further research.

vasopressin; receptor; pituitary


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ADRENOCORTICOTROPIN (ACTH), a key regulator of the hypothalamo-pituitary-adrenal axis, is expressed in the corticotroph cells of the anterior pituitary, the release of which is stimulated by two hypothalamic factors, corticotropin-releasing hormone (CRH) and vasopressin (9). Recently, various subtypes of receptors for CRH and vasopressin have been identified, with subsequent cloning of the genes being almost completed. Among the receptor subtypes, CRH-R1 and V1b vasopressin receptors are known to be expressed in the corticotroph cells of the pituitary (14, 19, 25). It has also been shown that both hormones are involved in the synthesis and secretion of ACTH through specific receptors (17).

The expression of ACTH, however, is not solely determined by the extracellular levels of CRH and/or vasopressin. It is well known that chronic stimulation of a hormone, in general, alters the expression of its own or related receptors, and indeed CRH has been shown to decrease the expression of CRH-R1 receptor mRNA (26). In this sense, it is also important to clarify the regulation of the V1b vasopressin receptor for complete understanding of the regulation of ACTH at the corticotroph level.

For this purpose, in this study we cloned, sequenced, and characterized the 5'-flanking region of the rat V1b vasopressin receptor gene. The DNA we cloned showed substantial transcriptional activity in the AtT-20 cell, indicating that the region is the 5'-promoter of the V1b receptor gene. More interestingly, multiple upstream open reading frames (uORFs) were found to be located in the 5'-untranslated region (5'-UTR) of the gene, and some of these were shown to have potent inhibitory effects on V1b receptor expression.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cloning and sequencing. An ~5 kb of the upstream region of the rat V1b vasopressin receptor gene (25) was subcloned into the pBluescript plasmid vector (Stratagene, La Jolla, CA) and sequenced by an ABI PRISM 310 genetic analyzer (Perkin-Elmer, Foster City, CA) with a BigDye Terminator Cycle Sequencing Reaction kit (Perkin-Elmer).

5'-Amplification of cDNA ends. The transcription start site(s) of the rat V1b vasopressin receptor gene was determined by 5'-amplification of cDNA ends (RACE) by use of a Marathon cDNA amplification kit (Clontech, Palo Alto, CA). Total RNA was extracted from the Sprague-Dawley rat pituitary gland with TRIzol reagent (Life Technologies, Grand Island, NY), and poly(A)+ RNA was isolated using the poly(A) quick mRNA isolation kit (Stratagene). Then double-stranded cDNA synthesis and adapter ligation were performed, and the product was used as a template for the RACE analysis. PCR was performed using the AP1 primer (provided by the supplier) and the gene-specific antisense primer (5'-CAGTAGCTAGGATACCGATCTCC-3') complementary to the published nucleotide sequence of the rat V1b receptor cDNA (25). Finally, the PCR product was cloned into pCR2.1 using the TA Cloning kit (Invitrogen, Carlsbad, CA), and >10 clones were isolated for nucleotide sequencing. If multiple clones had the same sequence starting at the most upstream region of the 5'-UTR, the 5'-end was recognized as the transcription start site.

Plasmid construction. Various lengths of the promoter region of the V1b vasopressin receptor gene were obtained by digestion with appropriate restriction enzymes and subcloned into the plasmid containing luciferase reporter gene, pA3Luc (15). Inactivation of one or more translation start site(s) of the uORFs was performed using PCR-based site-directed mutagenesis (7), in which ATG was changed to TTG, ACG, ATT, and CTG for uORF-1, -2, -3, and -4, respectively. To see the translational activity of each uORF, the coding sequence of the luciferase protein was directly linked to the initiation codon of each uORF. For testing the function of each uORF in the heterologous context, the region containing an individual uORF (nucleotide positions between -472 and -345 for uORF-1 and -2, between -364 and -213 for uORF-3, and between -230 and -46 for uORF-4) was isolated and inserted between the Raus sarcoma virus (RSV) long terminal repeat promoter and luciferase reporter gene in pA3Luc. To check the sequence dependency of the function of uORFs, a construct in which the nucleotide sequences of the uORF-3 were replaced with the partial sequence of beta -lactamase was made and used as a representative one. Finally, constructs containing 5'-UTR with uORF-1 to -4 (between -472 and -1), in which all or all but one (uORF-3) of the ATGs were inactivated, were used in the mRNA expression experiment.

Cell culture and transfection. The murine corticotroph tumor cell line AtT-20/D16v (AtT-20) was maintained in a T75 culture flask with Dulbecco's modified Eagle's medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies) and antibiotics (50 µU/ml penicillin and 50 µg/ml streptomycin; Life Technologies) under 5% CO2-95% atmosphere at 37°C. Culture medium was changed twice a week, and the cells were subcultured once a week.

In each experiment, the cells were plated in 3.5-cm-diameter culture dishes, and transient transfection was performed using TransIT polyamine transfection reagent (Pan Vera, Madison, WI). The beta -galactosidase (beta -gal) or secreted placental alkaline phosphatase (SEAP) (pSEAP2-control, Clontech) expression plasmids were used as an internal control. At the end of each experiment, cells were harvested and applied for luciferase assay. The difference in transfection efficiency among the constructs was corrected by beta -gal or SEAP activity.

Northern blot analysis. Northern blot analysis was performed essentially as previously described (27). Briefly, total RNA was isolated from the cells transfected with V1b-luciferase (RSVORF- or RSVORF3+) and pSEAP2-control plasmids by use of the RNeasy RNA extraction kit (Qiagen, Hilden, Germany). Fifteen micrograms of the RNA were denatured and electrophoresed with 1% agarose gel and then transferred to a nylon membrane (GeneScreen Plus, NEN, Boston, MA), followed by prehybridization at 42°C for 3 h. Antisense oligonucleotide probes complementary to the coding sequences of the luciferase or of the rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were labeled with [alpha -32P]dCTP by use of the Nick Translation System (Promega, Madison, WI). Hybridization was performed at 42°C for 20 h in a rotating bottle of the hybridization oven. Membranes were then washed, and the signals were densitometrically quantified using a Bioimage analyzer (BAS-2000, Fuji Photo Film, Tokyo, Japan), with subsequent normalization against a corresponding relative amount of GAPDH mRNA in each sample. The values were also normalized with transfection efficiency determined by the SEAP activity.

Reporter assays. Luciferase assay was performed as previously described (1). SEAP activity was determined using the SEAP reporter assay kit (Toyobo, Osaka, Japan). The beta -gal activity was determined by Galacto-Light Plus beta -gal assay kit (Tropix, Bedford, MA).

Data analysis. Samples in each group of the experiments were in triplicate or quadruplicate. All data were expressed as means ± SE. When statistical analyses were performed, data were compared by one-way ANOVA with Fisher's protected least significant difference test, and P values <0.05 were considered significant.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Determination of the nucleotide sequences and gene structure of the 5'-flanking region and 5'-UTR of the rat V1b vasopressin receptor gene. Approximately 5 kb of the upstream region of the rat V1b vasopressin receptor gene were sequenced and deposited in the GenBank database (accession number AB042197). Figure 1 shows the nucleotide sequences of the downstream region (-1000 to +3; +1 designates the translation start site of the open reading frame encoding the V1b receptor protein). 5'-RACE identified the major transcriptional start site 801 bp upstream from the authentic translation start site. There was no TATA box, but stretches of CT or CA repeats were recognized near the transcription start site. In addition, comparison of the sequences with the sequence of cDNA revealed a new intron within the 5'-UTR (-769 to -608). Furthermore, analysis of the sequences of the 5'-UTR showed five uORFs that precede the major ORF encoding the V1b receptor protein.


View larger version (80K):
[in this window]
[in a new window]
 
Fig. 1.   Nucleotide sequences of the rat V1b vasopressin receptor gene 5'-promoter and 5'-untranslated region (UTR). Italic, bold, and lower case letters designate the 5'-promoter, 5'-UTR, and intron, respectively. The major transcription start site is circled. Boxes and underlines indicate the initiation and termination codon, respectively. +1 designates the first nucleotide of the translation start site of the major open reading frame (ORF) for V1b protein.

Serial deletion analysis of the transcriptional activity of the rat vasopressin V1b receptor gene 5'-promoter. The transcriptional activities of the various lengths of the 5'-promoter region of the cloned gene were examined using the AtT-20 mouse corticotroph cell line. As shown in Fig. 2, substantial luciferase activity was obtained in all of the constructs compared with the promoterless vector. Serial deletion revealed that the promoter activity was highest in the second shortest construct examined (-1641--444) and was still maintained in the shortest construct examined (-1173--444). These results indicate that the region examined is indeed a 5'-promoter of the V1b vasopressin receptor gene and that the area between -1173 and -444 appears to be enough for the basal promoter activity.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of serial deletion of the rat V1b vasopressin receptor 5'-promoter (-4894, -3366, -2663, -1641, -1173) on basal transcriptional activity in corticotroph cells. AtT-20 cells were transfected transiently with various lengths of the rat V1b vasopressin receptor 5'-promoter luciferase (Luc) fusion gene. Values were normalized by beta -galactosidase (beta -gal) activity used as an internal control.

Characterization of the function of the uORFs in the 5'-UTR of the V1b vasopressin receptor mRNA. As mentioned above, nucleotide sequences of the 5'-UTR showed the presence of multiple uORFs (designated as uORF-0 to -5), and thus we tried to see whether any of the uORFs would influence the expression of the V1b receptor. We focused on uORFs-1 to -4, because the first one (uORF-0) is very close to the transcription start site. When the 5'-flanking region with or without the uORFs was subcloned into the luciferase vector and expressed in AtT-20 cells, luciferase activity was much lower in the construct with uORFs (WT) than in that without them (Delta ORFs) (Fig. 3), indicating the inhibitory nature of some of the uORF(s).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   A: schematic representation of the upstream ORFs (uORFs) in the 5'-UTR of the V1b vasopressin receptor gene. Wild-type (WT) construct contains the uORFs (uORF-1 to -4), whereas the Delta ORF construct does not. B: luciferase expression of the WT and Delta ORFs in AtT-20 cells. Values were normalized by beta -gal activity. *P < 0.05 vs. Delta ORFs.

We then examined which uORF was responsible for the inhibitory effect by using mutated constructs in which the initiation codon of each uORF was individually inactivated by introducing a point mutation within ATG. As shown in Fig. 4, abrogation of either of the ATGs did not restore the luciferase expression, indicating that more than one uORF is responsible for the suppression. Further investigations using different series of mutated constructs in which all but one uORF was inactivated or deleted showed that uORF-1 had no effect and that uORF-2 had a mild inhibitory effect, although it did not reach statistical significance (Fig. 5A). In contrast, constructs with either uORF-3 or uORF-4 showed inhibitory effects (Fig. 5B).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of inactivation of the initiation codon of each uORF on luciferase expression. WT or mutated (Delta ORFs, M1, M2, M3, M4) constructs were transfected into the AtT-20 cells, and luciferase activity was determined. Values were normalized by beta -gal activity. Circles and crosses designate the intact and inactivated initiation codons, respectively. *P < 0.05 vs. Delta ORFs.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of individual uORFs on luciferase expression in AtT-20 cells. A: comparison of luciferase expression among constructs in which none (Delta 1/2), only uORF-1 (ORF1), or only uORF-2 (ORF2) is intact. uORF-3 and -4 are deleted in all constructs. B: comparison of luciferase expression among constructs in which none (Delta ORFs), only uORF-3 (ORF3), or only uORF-4 (ORF4) is intact. C: translational activity of the uORF-3 and -4. The initiation codon of either uORF-3 or -4 was directly linked to luciferase protein (ORF3AUG, ORF4AUG), and expression of luciferase protein was compared with that of Delta ORFs. *P < 0.05 vs.Delta ORFs.

When the nucleotide sequence contexts around the initiation codons of each uORF were compared, those of uORF-3 and -4 were in preferable context with Kozak's consensus sequence (Table 1) (11). Therefore, we tried to see whether the uORF-3 and -4 functioned as translation initiation sites by directly linking the initiation codon of each uORF with luciferase protein. The results showed that uORF-3 and -4 actually were translationally active, although weaker than Delta ORFs (Fig. 5C). These results suggest that the two downstream uORFs are mainly responsible for the inhibitory effect.

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Comparison of the nucleotide sequences around each ATG with Kozak's consensus sequence

Effect of the uORFs in the context of a heterologous promoter. To see whether the negative effect of the uORFs is exhibited only in the V1b vasopressin receptor gene or is still functional in a heterologous context, a series of constructs in which the DNA fragments containing each uORF were individually located downstream of the RSV promoter were expressed in AtT-20 cells. The results showed a pattern virtually similar to that of the V1b vasopressin gene: mild suppressive effect with uORF-2, and potent inhibition with both uORF-3 and -4 (Fig. 6, A and B). Thus the suppression is valid in a heterologous context as well, suggesting a common mechanism in the inhibitory effect of the uORFs.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of an individual uORF in a heterologous promoter on luciferase expression in AtT-20 cells. A: the 5'-UTR of the V1b vasopressin receptor gene containing uORF-1 and -2 was isolated and inserted between the Raus sarcoma virus (RSV) promoter and luciferase reporter gene. Because uORF-1 and -2 overlap, the insert section contains both uORFs, but the initiation codon of either uORF-1 (RSVORF1) or uORF-2 (RSVORF2) is made intact. The luciferase expression of the constructs was compared with that without uORF (RSVDelta ORFs). B: the 5'-UTR of the V1b vasopressin receptor containing uORF-3 or -4 was isolated and inserted between the RSV promoter and the luciferase reporter gene. Luciferase expression of constructs was compared with that without uORF (RSVDelta ORFs). C: the coding sequence of uORF-3 except initiation and stop codons was replaced with an unrelated one (partial coding sequence of beta -lactamase) (RSVORF3R), and the suppressive effect was compared with the authentic one (RSVORF3A) or the construct without uORFs (RSVDelta ORFs). *P < 0.05 vs. RSVDelta ORFs.

In addition, we also examined whether the suppression depends on the nucleotide sequence within the ORFs. We chose uORF-3 as a representative one and replaced the sequence with a completely different one (partial coding sequence of beta -lactamase) (RSVORF3R). The results showed that the uORF-3 with an altered coding sequence still had an inhibitory effect (Fig. 6C), although it was less than the authentic uORF-3. Thus the inhibition is caused, at least partly, by a sequence-independent mechanism (i.e., occurrence of translation initiation itself).

To clarify the mechanism of inhibition more precisely, we tried to determine whether the effect of the uORFs is transcriptional or posttranscriptional. We used two new constructs in which the initiation codons of all 4 uORFs (RSVORF- ) or all but uORF3 (which showed the most potent inhibitory effect) were inactivated (RSVORF3+). When the two constructs were expressed in the AtT-20 cells, the level of luciferase mRNA determined by Northern blot analysis was comparable (Fig. 7). In contrast, the expression of luciferase protein determined by its activity was still lower in the construct with uORF-3. The results strongly suggest that the inhibition occurs not at the transcriptional but rather at the posttranscriptional, probably translational, level.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of uORF-3 on the expression of luciferase mRNA and protein. Constructs containing no uORF (RSVORF-) or only uORF-3 (RSVORF3+) were transfected into AtT-20 cells, and both mRNA and protein levels were determined by Northern blot analysis and luciferase assay, respectively. Photograph shows representative Northern blot of luciferase mRNA. *P < 0.05 vs. RSVORF-.

Possible regulation of V1b receptor expression by intracellular calcium through the uORFs. Finally, to see whether the uORF-mediated inhibition is associated with a specific regulatory process, we examined the responsiveness of V1b promoter-luciferase protein expression to increased intracellular calcium by thapsigargin, which mimics the stimulation of corticotroph with vasopressin through the V1b receptor. In the construct with uORFs (WT), treatment of the cells with thapsigargin significantly increased the V1b-luciferase expression (Fig. 8), whereas no response was found in that without uORFs (Delta ORFs). This suggests that an intracellular calcium-mediated signaling pathway might regulate the expression of the V1b receptor posttranscriptionally through the uORFs.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of increase in intracellular calcium on expression of luciferase protein. Constructs with (WT) or without uORFs (Delta ORFs) were treated with thapsigargin (2 µM) or vehicle for 5 h. Open and closed bars represent cells treated with vehicle or thapsigargin, respectively. *P < 0.05 vs. vehicle-treated group.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In this paper, we cloned the 5'-promoter and 5'-UTR of the rat V1b vasopressin receptor gene and determined the nucleotide sequences up to 5 kb from the translation start site. Using the cloned gene, we confirmed that the 5'-promoter region actually has transcriptional activity in the corticotroph cell line AtT-20. Interestingly, the 5'-UTR of the gene has multiple uORFs, some of which are found to exert inhibitory effects on protein synthesis. Our results raise the possibility that the expression of the V1b receptor is regulated not only at the transcriptional but also at the posttranscriptional level.

The vasopressin receptor consists of three subtypes, i.e., V1a, V1b, and V2 (28). The V2 receptor plays a key role in the regulation of water reabsorption at the collecting duct of the kidney (10), whereas the V1a receptor is thought to be involved in cardiovascular regulation (6). The V1b receptor, on the other hand, is expressed mainly in the corticotroph of the anterior pituitary, where it mediates the effect of vasopressin on ACTH secretion (21). In this study, our data clearly indicate by use of the luciferase reporter system that the area we examined indeed has promoter activity in corticotroph cells. It is a TATA-less promoter, and ~0.35 kb from the transcription start site (between -1173 and -801) seems to be enough to maintain the basal promoter activity. Moreover, repressor and enhancer elements were suggested to be located in the regions -2663--1641 and -1641--1173, respectively. Interestingly, Rabadan-Diehl et al. (22) failed to find any transcriptional activity of the same promoter in AtT-20 cells.

The most interesting feature of the 5'-UTR sequences of the V1b vasopressin receptor gene is the location of five uORFs preceding the initiation codon of the major ORF, which is relatively uncommon in mRNA of vertebrate cells. Initially, we tried to characterize the transcriptional regulation of the V1b promoter region by using the constructs with the uORFs, and we found very low promoter activity. Subsequently, however, when the area containing uORFs (uORF-1 to uORF-4) was eliminated from the construct, high basal activity was consistently obtained, suggesting that some of the uORFs have an inhibitory effect on protein expression. Extensive examinations by mutating the translation start sites of each uORF revealed that the two downstream uORFs (uORF-3 and -4) seemed to mediate the suppressive effect in both homologous and heterologous contexts. In fact, when the sequences around the initiation codon of each uORF were compared with Kozak's consensus (11), those of the two downstream uORFs were in favorable context (Table 1). Furthermore, the expression of the protein product (luciferase) in the construct with intact uORF-3 was much decreased compared with that with the inactivated one despite the comparable levels of mRNAs, suggesting strongly that the suppression by the uORF is occurring at the posttranscriptional level.

The mechanism(s) whereby these uORFs are involved in the suppressive effect is not entirely clear. In general, one mRNA harbors a unique ORF, and <10% of the vertebrate mRNA has uORF(s) (12). However, it is reported that uORFs are found with a relatively high frequency in the 5'-UTR of the G protein-coupled receptor (GPCR) genes such as CRH, angiotensin II, and beta 2-adrenergic receptors (3, 13, 16, 18, 29). If an mRNA has uORF(s), it is expected that the uORF(s) somehow interferes with the function of the major ORF, because re-initiation of translation is not common in eukaryocytes. Two major possible mechanisms regarding the function of uORF(s) are proposed. The first possibility is that the product of the uORF(s) (a small peptide) interferes with the initiation of the authentic ORF (4, 24). The second one is that the initiation at the uORF(s) by itself inhibits the re-initiation at downstream ORF (2, 3, 8). Our data show that the inhibition occurred mainly at the uORFs with Kozak's consensus (11), and actually uORF-3 and -4 were functional in terms of translation. We also found that replacement of the coding sequence of uORF3 with a completely different one (RSVORF3R) still had a significant suppressive effect, supporting the second possibility (sequence-independent event). However, the sequence-dependent mechanism cannot completely be ruled out, because the degree of inhibition was significantly less in RSVORF3R than in RSVORF3A.

Another interesting point is whether any kind of regulatory mechanism(s) involves the function of uORF(s). In some cases, such as carbamoyl-phosphate synthetase or S-adenosylmethionine decarboxylase mRNAs, the inhibition through uORF(s) is shown to be regulated by the metabolic milieu within the cell (4, 24). Because uORFs are sometimes found in the GPCR or other types of receptor genes (13), including our case, it may be possible that the preceding uORF(s) is regulating the expression of the major ORF by switching its translation on and off. In our study, the expression of the V1b vasopressin receptor constructs containing the uORFs was potently suppressed at the posttranscriptional level in AtT-20 cells. However, because the V1b receptor mRNA containing the same uORFs is normally expressed in the corticotroph cells in vivo, there should be some mechanism(s) for releasing the inhibition by uORFs. In fact, a discrepancy between the levels of mRNA and binding capacity in vivo has been suggested, further indicating the additional posttranscriptional regulatory step(s) (20, 23). Our data showed the increase in V1b-luciferase expression by thapsigargin, suggesting that vasopressin-induced rise in intracellular calcium through the V1b receptor might regulate the expression of the receptor itself through an uORF-mediated posttranscriptional mechanism. We could not confirm this hypothesis in this study, because AtT20 cells did not express a functional V1b vasopressin receptor (data not shown).

CRH and vasopressin, the two major positive regulators of ACTH secretion, exert their effects through different intracellular signaling pathways, i.e., the cAMP/protein kinase A and the phosphoinositide/Ca2+ pathways, respectively. Furthermore, the cross talk between the two pathways has also been shown (5). In this sense, it is possible that one ligand influences the expression of the receptor of the other ligand(s), and indeed the administration of CRH is shown to decrease the V1b receptor mRNA as well as that of the CRH-R1 receptor (26). Interestingly, the mRNA of the CRH-R1 receptor also has uORFs (29), and therefore we suppose that this kind of cross talk may be occurring through the uORFs. Investigation of the regulation of the CRH-R1 and V1b vasopressin receptors at both transcriptional and posttranscriptional levels will be necessary for the complete understanding of the molecular mechanism of the CRH-vasopressin interaction.


    FOOTNOTES

Address for reprint requests and other correspondence: Y. Iwasaki, Dept. of Clinical Laboratory Medicine, Nagoya Univ. School of Medicine and Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan (E-mail: iwasakiy{at}med.nagoya-u.ac.jp).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 8 June 2000; accepted in final form 22 January 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Aoki, Y, Iwasaki Y, Katahira M, Oiso Y, and Saito H. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. I. Effects of the common secretagogues. Endocrinology 138: 1923-1929, 1997[Abstract/Free Full Text].

2.   Child, SJ, Miller MK, and Gaballe AP. Translational control by an upstream open reading frame in the HER-2/neu transcript. J Biol Chem 274: 24335-24341, 1999[Abstract/Free Full Text].

3.   Curnow, KM, Pascoe L, Davies E, White PC, Corvol P, and Clauser E. Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. Mol Endocrinol 9: 1250-1262, 1995[Abstract].

4.   Delbecq, P, Werner M, Feller A, Filipkowski RK, Messenguy F, and Pierard A. A segment of mRNA encoding the leader peptide of the CPA1 gene confers repression by arginine on a heterologous yeast gene transcript. Mol Cell Biol 14: 2378-2390, 1994[Abstract].

5.   Gillies, GE, Linton EA, and Lowry PJ. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299: 355-357, 1982[ISI][Medline].

6.   Hasser, EM, Bishop VS, and Hay M. Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Clin Exp Pharmacol Physiol 24: 102-108, 1997[ISI][Medline].

7.   Higuchi, R, Krummel B, and Saiki K. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res 16: 7351-7367, 1988[Abstract].

8.   Hinnebusch, AG. Gene-specific translational control of the yeast GCN4 gene by phosphorylation of eukaryotic initiation factor 2. Mol Microbiol 10: 215-223, 1993[ISI][Medline].

9.   Holm, IA, and Majzoub JA. Adrenocorticotropin. In: The Pituitary, edited by Melmed S.. Cambridge, UK: Brackwell, 1995, p. 45-97.

10.   Knepper, MA, Kim GH, Fernandez-Llama P, and Ecelbarger CA. Regulation of thick ascending limb transport by vasopressin. J Am Soc Nephrol 10: 628-634, 1999[Free Full Text].

11.   Kozak, M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44: 283-292, 1986[ISI][Medline].

12.   Kozak, M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 15: 8125-8148, 1987[Abstract].

13.   Kozak, M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 115: 887-903, 1991[Abstract].

14.   Lolait, SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS, III, Mezey E, and Brownstein MJ. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci USA 92: 6783-6787, 1995[Abstract].

15.   Maxwell, IH, Harrison GS, Wood WM, and Maxwell F. A DNA cassette containing a trimerized SV40 polyadenylation signal which efficiently blocks spurious plasmid-initiated transcription. Biotechniques 7: 276-280, 1989[ISI][Medline].

16.   McGraw, DW, Forbes SL, Kramer LA, and Liggett SB. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 102: 1927-1932, 1998[Abstract/Free Full Text].

17.   Muglia, LJ, Jacobson L, Luedke C, Vogt SK, Schaefer ML, Dikkes P, Fukuda S, Sakai Y, Suda T, and Majzoub JA. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency. J Clin Invest 105: 1269-1277, 2000[Abstract/Free Full Text].

18.   Parola, AL, and Kobilka BK. The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem 269: 4497-4505, 1994[Abstract/Free Full Text].

19.   Perrin, MH, Donaldson CJ, Chen R, Lewis KA, and Vale WW. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 133: 3058-3061, 1993[Abstract].

20.   Rabadan-Diehl, C, and Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 139: 3220-3226, 1998[Abstract/Free Full Text].

21.   Rabadan-Diehl, C, Lolait SJ, and Aguilera G. Regulation of pituitary V1b vasopressin receptor mRNA during stress in the rat. J Neuroendocrinol 7: 903-910, 1995[ISI][Medline].

22.   Rabadan-Diehl, C, Lolait S, and Aguilera G. Isolation and characterization of the promoter region of the rat vasopressin V1b receptor gene. J Neuroendocrinol 12: 437-444, 2000[ISI][Medline].

23.   Rabadan-Diehl, C, Makara G, Kiss A, Lolait S, Zelena D, Ochedalski T, and Aguilera G. Regulation of pituitary V1b vasopressin receptor messenger ribonucleic acid by adrenalectomy and glucocorticoid administration. Endocrinology 138: 5189-5194, 1997[Abstract/Free Full Text].

24.   Ruan, H, Shantz LM, Pegg AE, and Morris DR. The upstream open reading frame of the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive translational control element. J Biol Chem 271: 29576-29582, 1996[Abstract/Free Full Text].

25.   Saito, M, Sugimoto T, Tahara A, and Kawashima H. Molecular cloning and characterization of rat V1b vasopressin receptor: evidence for its expression in extra-pituitary tissues. Biochem Biophys Res Commun 212: 751-757, 1995[ISI][Medline].

26.   Sakai, K, Horiba N, Sakai Y, Tozawa F, Demura H, and Suda T. Regulation of corticotropin-releasing factor receptor messenger ribonucleic acid in rat anterior pituitary. Endocrinology 137: 1758-1763, 1996[Abstract].

27.   Terashima, Y, Kondo K, Inagaki A, Yokoi H, Arima H, Murase T, Iwasaki Y, and Oiso Y. Age-associated decrease in response of rat aquaporin-2 gene expression to dehydration. Life Sci 62: 873-882, 1998[ISI][Medline].

28.   Thibonnier, M, Berti-Mattera LN, Dulin N, Conarty DM, and Mattera R. Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog Brain Res 119: 147-161, 1998[ISI][Medline].

29.   Tsai-Morris, CH, Buczko E, Geng Y, Gamboa-Pinto A, and Dufau ML. The genomic structure of the rat corticotropin releasing factor receptor. A member of the class II G protein-coupled receptors. J Biol Chem 271: 14519-14525, 1996[Abstract/Free Full Text].


Am J Physiol Endocrinol Metab 280(5):E780-E787
0193-1849/01 $5.00 Copyright © 2001 the American Physiological Society